Evidence map›Paper›PMID 36003787›Full record

ArticleFrontiers in oncology2022

Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication.

Patrick Mayr, Mathias Lutz, Maximilian Schmutz, Jens Hoeppner, Friederike Liesche-Starnecker, Jürgen Schlegel, Jochen Gaedcke, Rainer Claus

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Patrick MayrDepartment of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Mathias LutzDepartment of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Maximilian SchmutzDepartment of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Jens HoeppnerDepartment of Surgery, Medical Faculty Schleswig-Holstein, University of Schleswig-Holstein, Lübeck, Germany.
Friederike Liesche-StarneckerDepartment of Neuropathology, Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.
Jürgen SchlegelDepartment of Neuropathology, Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.
Jochen GaedckeDepartment of General and Visceral and Pediatric Surgery, Medical Faculty Göttingen, University of Göttingen, Göttingen, Germany.
Rainer ClausDepartment of Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
University of Augsburg · DETechnical University of Munich · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: JC virus reactivation causing progressive multifocal leukoencephalopathy (PML) occurs preferentially in human immunodeficiency virus (HIV) positive individuals or patients suffering from hematologic neoplasms due to impaired viral control. Reactivation in patients suffering from solid malignancies is rarely described in published literature. Case Presentation: Here we describe a case of PML in a male patient suffering from esophageal cancer who underwent neoadjuvant radiochemotherapy and surgical resection in curative intent resulting in complete tumor remission. The radiochemotherapy regimen contained carboplatin and paclitaxel (CROSS protocol). Since therapy onset, the patient presented with persistent and progredient leukopenia and lymphopenia in absence of otherwise known risk factors for PML. Symptom onset, which comprised aphasia, word finding disorder, and paresis, was apparent 7 months after therapy initiation. There was no relief in symptoms despite standard of care PML directed supportive therapy. The patient died two months after therapy onset. Conclusion: PML is a very rare event in solid tumors without obvious states of immununosuppression and thus harbors the risk of unawareness. The reported patient suffered from lymphopenia, associated with systemic therapy, but was an otherwise immunocompetent individual. In case of neurologic impairment in patients suffering from leukopenia, PML must be considered - even in the absence of hematologic neoplasia or HIV infection.

Indexed as

chemotherapycomplicationesophageal cancerJC virus(literature) reviewlymphopeniaprogressive multifocal leukoencephalopathysolid tumor

Identifiers

PMID36003787
PMCPMC9394442
OpenAlexW4289522591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.